Zejing Pharmaceutical announced that clinical data on ZG005, ZG006 and ZGGS34 independently developed by the company and the latest developments will be released at the annual meeting of the European Society of Medical Oncology to be held from October 23 to 27, 2026. Among patients with small cell lung cancer, ZG006 confirmed the ORR of 75.0%, 61.1%, and 91.7% in the 10 mg, 30 mg, and 60 mg Q2W groups, respectively; a key phase III study on ZG005 combined with EP to treat first-line advanced neuroendocrine cancer has been initiated; the ZGGS34 study is currently being carried out in China and continues to recruit trial participants.
Zhitongcaijing · 3d ago
Share
Listen to the news
Zejing Pharmaceutical announced that clinical data on ZG005, ZG006 and ZGGS34 independently developed by the company and the latest developments will be released at the annual meeting of the European Society of Medical Oncology to be held from October 23 to 27, 2026. Among patients with small cell lung cancer, ZG006 confirmed the ORR of 75.0%, 61.1%, and 91.7% in the 10 mg, 30 mg, and 60 mg Q2W groups, respectively; a key phase III study on ZG005 combined with EP to treat first-line advanced neuroendocrine cancer has been initiated; the ZGGS34 study is currently being carried out in China and continues to recruit trial participants.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending